Diabete Type 2

1
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Rivus Pharmaceuticals
Rivus PharmaceuticalsVA - Charlottesville
1 program
1
HU6Phase 21 trial
Active Trials
NCT06104358WithdrawnEst. Mar 2025
Verona Pharma
Verona PharmaUK - London
1 program
Gel therapy after non surgical therapyN/A1 trial
Active Trials
NCT07372677Recruiting70Est. Jan 2030

Trial Timeline

Clinical trial activity over time

2023
2024
2025
2026
2027
2028
2029
2030
Rivus PharmaceuticalsHU6
Verona PharmaGel therapy after non surgical therapy

Clinical Trials (2)

Total enrollment: 70 patients across 2 trials

Ph 2a Study of HU6 on Energy Metabolism, Muscle and Liver Substrate Metabolism, and Mitochondrial Function in Subjects Who Are Overweight or Obese With Type 2 Diabetes

Start: Nov 2023Est. completion: Mar 2025
Phase 2Withdrawn
NCT07372677Verona PharmaGel therapy after non surgical therapy

Pocket-X Gel Non-surgical Periodontal Therapy

Start: Jun 2025Est. completion: Jan 203070 patients
N/ARecruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 70 patients
2 companies competing in this space